10-K: Avai Bio, Inc. Files Annual Report for FY 2026

Avai Bio, Inc. (formerly Avant Technologies Inc.) filed its annual report on Form 10-K for the fiscal year ended March 31, 2026, detailing its AI technology focus, financial performance, and forward-looking strategies.

Summary

• Avai Bio, Inc. (formerly Avant Technologies Inc.) has filed its annual report for the fiscal year ended March 31, 2026.
• The company is focused on acquiring, developing, and utilizing artificial intelligence (AI) technologies and providing IT consulting services.
• Key acquisitions include Avant! AI and Instant Fame Assets, along with a joint venture with Ainnova Tech Inc. and a license agreement with SGAustria Pte. Ltd. for biotech ventures (Klothonova and Insulinova).
• The company reported a net loss of $1,749,509 for the fiscal year ended March 31, 2026, compared to a net loss of $1,142,115 for the prior year.
• Operating expenses decreased by 3% to $1,480,191 in fiscal year 2026, primarily due to lower consulting services and amortization.
• The company had cash of $23,145 as of March 31, 2026, and a working capital deficit of $3,298,511.
• Management anticipates needing approximately $10,000,000 to fully implement its business plan and expects to raise additional capital through equity or debt financings.
• The company has identified material weaknesses in its internal controls, including the lack of an audit committee, insufficient cash controls, and inadequate IT controls.

Sentiment

Score: 3

Explanation: StockSavvy.ai views this filing as having a negative sentiment due to the increased net loss, declining cash reserves, widening working capital deficit, and identified material weaknesses in internal controls, despite strategic AI initiatives.

Positives

• The company is actively pursuing AI and technology development through strategic acquisitions and joint ventures.
• Operating expenses decreased by 3% to $1,480,191 in fiscal year 2026 compared to the previous year.
• The company has established joint ventures in biotech (Klothonova and Insulinova) with SGAustria Pte. Ltd., indicating diversification efforts.
• The company has a clear strategy to raise approximately $10,000,000 to fund its business plan and growth.

Negatives

• The company incurred a net loss of $1,749,509 for the fiscal year ended March 31, 2026, an increase of 53% from the prior year's loss of $1,142,115.
• The company has a limited operating history and has not achieved profitability, with a significant accumulated deficit of $5,868,019 as of March 31, 2026.
• The company has not generated positive cash flow from operations and has a working capital deficit of $3,298,511 as of March 31, 2026.
• The company's cash balance was only $23,145 as of March 31, 2026, raising concerns about its ability to meet short-term obligations.
• Material weaknesses in internal controls over financial reporting have been identified, including the absence of an audit committee and inadequate cash and IT controls.
• The company's stock is traded on the OTC QB marketplace, which is associated with higher volatility and potential difficulty in selling shares.

Risks

• The company has a limited operating history in an evolving industry, making future prospects difficult to evaluate and increasing the risk of failure.
• The company has not achieved profitability and may not be able to do so in the future, with expected continued net losses and increasing working capital deficiency.
• The company has not generated positive cash flow from operations and its ability to do so is uncertain, posing a risk of forced suspension or discontinuation of operations if capital is insufficient.
• The company requires substantial additional capital to support business growth and operations, and this capital may not be available on acceptable terms, if at all.
• The company depends on key personnel and the inability to attract and retain them could adversely affect business operations.
• The company's common stock is traded on the OTC QB marketplace, which can lead to significant volatility and difficulty in selling shares.
• The company has identified material weaknesses in its internal controls, which could lead to inaccurate financial reporting or fraud, eroding investor confidence.
• The company may be unable to commercialize its acquired technologies, such as Avant! AI and InstantFAME, despite significant investment.

Future Outlook

The company expects to require additional capital to support business growth and operations, estimating a need of approximately $10,000,000 to fully implement its business plan. Management plans to raise this capital through equity or debt financings. The company anticipates that net losses will continue in the near future.

Management Comments

• Management believes its AI technology can provide a self-sustained system that improves data efficiency and offers true learning from experience and reasoning capabilities.
• Management is developing plans to alleviate negative trends and conditions, but there is no assurance of success or curtailment of losses.
• Management expects to raise additional capital through equity or debt securities to fund operating requirements.
• Management has concluded that the company did not maintain effective internal control over financial reporting as of March 31, 2026, due to identified material weaknesses.

Industry Context

StockSavvy.ai notes that Avai Bio, Inc. is operating in the rapidly evolving AI and technology consulting sector. The company's strategy of acquiring and developing AI technologies aligns with broader industry trends, but its financial performance indicates significant challenges in achieving profitability and sustainable operations, common among early-stage tech companies in this space.

Comparison to Industry Standards

• The company's lack of revenue and net losses are not uncommon for early-stage technology and AI companies, but the scale of the accumulated deficit and working capital deficiency are significant.
• Many AI startups require substantial venture capital funding, and Avai Bio's stated need for $10 million aligns with typical funding requirements for scaling technology ventures.
• The identified material weaknesses in internal controls are a concern, as robust financial reporting and controls are standard expectations for publicly traded companies, even smaller ones.

Corporate Governance

Legal Proceedings

• There is currently no litigation that management believes will have a material impact on the financial position of the Company.

Related Party Transactions

• As of March 31, 2026, directors and officers had loaned a total of $744,420 to the Company for working capital.
• A related party loan from IGOR 1 CORP of $471,529 was outstanding as of March 31, 2026, and was settled on March 30, 2026, by issuing 12,459,000 common shares.
• Advances totaling $124,590 were received from former president Andrii Kokliushyn during the year ended March 31, 2020, which were interest-free and due on demand.

Stakeholder Impact

• Shareholders may experience significant dilution due to future equity offerings needed to raise capital.
• Shareholders may face increased stock price volatility due to trading on the OTC QB marketplace.
• Employees' job security may be impacted by the company's ongoing financial challenges and need for capital.
• Creditors and lenders face increased risk given the company's substantial debt and working capital deficit.

Next Steps

• Raise approximately $10,000,000 to fund business plan implementation and operations.
• Continue to develop and acquire innovative AI technologies.
• Seek third parties for licensing, acquisition, or joint ventures for the Technology Portfolio.
• Address material weaknesses in internal controls over financial reporting.

Key Dates

Recommendation

While Avai Bio is pursuing innovative AI technologies, the company's significant net losses, declining cash position, substantial working capital deficit, and identified material weaknesses in internal controls present considerable risks. The need for substantial future capital raises concerns about dilution and financial stability. Therefore, a 'hold' recommendation is appropriate, pending evidence of improved financial performance, successful capital raises, and remediation of internal control deficiencies.

Keywords

Avai Bio, Form 10-K, Annual Report, Artificial Intelligence, AI Technology, Venture Capital, Biotechnology, Financial Statements